Printed on 7/20/2026
For informational purposes only. This is not medical advice.
HAM-A is a clinician-rated anxiety severity instrument scoring psychic and somatic anxiety domains across 14 items, each rated 0 to 4.
Formula: HAM-A total = sum of 14 item scores (0-56).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
A trained clinician rates each of 14 items covering psychic anxiety (items 1-7: anxious mood, tension, fears, insomnia, concentration, depressed mood) and somatic anxiety (items 8-14: muscular, sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic symptoms, and behavior at interview) based on a structured clinical interview.
Each item is rated on a 5-point scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. Total HAM-A score is the sum of all 14 items, ranging 0-56.
Score interpretation: ≤17 = mild; 18-24 = mild to moderate; 25-30 = moderate to severe; ≥31 = severe anxiety. A clinically meaningful change (MCID) is typically ≥7 points. Response = ≥50% reduction from baseline; remission = score ≤7.
Clinical Researchers
HAM-A is required as a primary or secondary endpoint in many FDA clinical trial submissions for anxiolytic drugs and GAD treatments, providing a standardized clinician-rated measure of anxiety severity change.
Psychiatrists & Clinical Pharmacologists
Serial HAM-A administration quantifies response to SSRIs, SNRIs, buspirone, and benzodiazepines in clinical practice and trials, with response defined as ≥50% reduction and remission as score ≤7.
Psychiatrists & Psychologists
HAM-A provides a comprehensive clinician-rated baseline of anxiety severity at treatment initiation, enabling objective measurement of subsequent improvement or deterioration across 14 specific symptom domains.
Mental Health Clinicians & Researchers
As a standardized scale with established psychometric properties, HAM-A enables meaningful comparison of anxiety severity between baseline, mid-treatment, and end-of-treatment assessments in longitudinal clinical care.
Regulatory Affairs & Drug Developers
The FDA requires HAM-A as a primary efficacy measure in most generalized anxiety disorder (GAD) clinical trials. It provides the regulatory standard against which anxiolytic drug efficacy must be demonstrated.
HAM-A requires a trained clinician to rate symptoms based on interview and observation. Self-administration by patients produces invalid results. This distinguishes HAM-A from GAD-7, which is validated for patient self-report. Always clarify this distinction when implementing in clinical workflows.
For routine primary care and outpatient mental health screening, GAD-7 (7-item self-report) has largely replaced HAM-A due to its self-report convenience, established screening thresholds, and equivalent sensitivity to change. HAM-A remains the standard in clinical trials and research settings.
HAM-A contains two subscales: psychic anxiety (items 1-6) measuring cognitive and psychological anxiety, and somatic anxiety (items 7-13) measuring physical symptoms. The somatic subscale may be more influenced by medical comorbidities; tracking both subscales separately helps identify whether improvement is primarily psychological or physical.
A minimum clinically important difference (MCID) of approximately 7 HAM-A points is considered clinically meaningful in research contexts. Response is conventionally defined as ≥50% reduction from baseline, and remission as total score ≤7 or ≤10 depending on the study.
NICE guidelines and APA guidelines recommend SSRIs (sertraline, escitalopram, paroxetine) and SNRIs (duloxetine, venlafaxine) as first-line pharmacotherapy for GAD, combined with cognitive behavioral therapy (CBT). CBT alone or pharmacotherapy alone are both effective, but combination therapy produces the best outcomes.
While benzodiazepines rapidly reduce anxiety, they are associated with tolerance, physiological dependence, cognitive impairment, and falls in elderly patients. Use only short-term (maximum 2-4 weeks) for acute anxiety while waiting for SSRIs/SNRIs to take effect, not as maintenance treatment.
Buspirone is an anxiolytic without dependence potential, useful for GAD maintenance treatment in patients where benzodiazepine risk is a concern. Onset is slower (2-4 weeks) than benzodiazepines — patients must be counseled about delayed effect to prevent premature discontinuation.
HAM-A inter-rater reliability is moderate (κ = 0.74-0.92) and requires assessor training for consistency, particularly in research contexts. Clinical trials typically require assessor certification and regular calibration sessions to maintain reliability. Untrained administration undermines data quality.
HAM-A developed by Hamilton (Br J Med Psychol 1959). Clinician-rated; reliability κ varies (0.74-0.92). Widely used as primary endpoint in anxiety disorder clinical trials. GAD-7 (Spitzer et al., Arch Intern Med 2006) has largely replaced HAM-A in primary care due to self-report convenience. Response/remission criteria: Bandelow (Psychopharmacology 2006). NICE anxiety guidelines recommend SSRIs/SNRIs as first-line pharmacotherapy with CBT.
Higher HAM-A totals indicate greater anxiety severity and can support treatment-intensity and follow-up planning.
Use in clinician-led anxiety evaluation and longitudinal symptom tracking contexts.
HAM-A requires interviewer consistency and can be influenced by overlapping somatic symptoms from medical conditions; it is not a standalone diagnostic test.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Free GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).
OpenMental HealthQuick two-question anxiety screen using the GAD-2. A score of 3 or higher suggests further evaluation with the full [GAD-7](/tools/gad7).
OpenMental HealthFree PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
Open